HADDL_PSES4
ID HADDL_PSES4 Reviewed; 307 AA.
AC O06652;
DT 01-MAR-2004, integrated into UniProtKB/Swiss-Prot.
DT 01-JUL-1997, sequence version 1.
DT 25-MAY-2022, entry version 51.
DE RecName: Full=2-haloacid dehalogenase, configuration-inverting;
DE EC=3.8.1.10;
DE AltName: Full=DL-2-haloacid dehalogenase;
DE AltName: Full=DL-DEXi;
OS Pseudomonas sp. (strain 113).
OC Bacteria; Proteobacteria.
OX NCBI_TaxID=59918;
RN [1]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND MUTAGENESIS.
RX PubMed=9209038; DOI=10.1128/jb.179.13.4232-4238.1997;
RA Nardi-Dei V., Kurihara T., Park C., Esaki N., Soda K.;
RT "Bacterial DL-2-haloacid dehalogenase from Pseudomonas sp. strain 113: gene
RT cloning and structural comparison with D- and L-2-haloacid dehalogenases.";
RL J. Bacteriol. 179:4232-4238(1997).
CC -!- FUNCTION: Dehalogenates both (S)- and (R)-2-haloalkanoic acids to the
CC corresponding (R)- and (S)-hydroxyalkanoic acids, respectively, with
CC inversion of configuration at C-2. Acts on 2-haloalkanoic acids whose
CC carbon chain lengths are five or less.
CC -!- CATALYTIC ACTIVITY:
CC Reaction=an (S)-2-haloacid + H2O = a (2R)-2-hydroxycarboxylate + a
CC halide anion + H(+); Xref=Rhea:RHEA:11192, ChEBI:CHEBI:15377,
CC ChEBI:CHEBI:15378, ChEBI:CHEBI:16042, ChEBI:CHEBI:58314,
CC ChEBI:CHEBI:137405; EC=3.8.1.10;
CC -!- CATALYTIC ACTIVITY:
CC Reaction=an (R)-2-haloacid + H2O = a (2S)-2-hydroxycarboxylate + a
CC halide anion + H(+); Xref=Rhea:RHEA:22188, ChEBI:CHEBI:15377,
CC ChEBI:CHEBI:15378, ChEBI:CHEBI:16042, ChEBI:CHEBI:58123,
CC ChEBI:CHEBI:137406; EC=3.8.1.10;
CC -!- SUBUNIT: Homodimer.
CC -!- SIMILARITY: Belongs to the HAD-like hydrolase superfamily. S-2-
CC haloalkanoic acid dehalogenase family. {ECO:0000305}.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; U97030; AAB62819.1; -; Genomic_DNA.
DR AlphaFoldDB; O06652; -.
DR SMR; O06652; -.
DR BRENDA; 3.8.1.10; 5085.
DR GO; GO:0018784; F:(S)-2-haloacid dehalogenase activity; IEA:RHEA.
DR GO; GO:0018778; F:DL-2 haloacid dehalogenase activity; IEA:UniProtKB-EC.
DR InterPro; IPR019714; 2-haloacid_dehalogenase_DehI.
DR Pfam; PF10778; DehI; 1.
PE 1: Evidence at protein level;
KW Hydrolase.
FT CHAIN 1..307
FT /note="2-haloacid dehalogenase, configuration-inverting"
FT /id="PRO_0000079172"
FT MUTAGEN 26
FT /note="Y->F: 60% activity of wild-type."
FT /evidence="ECO:0000269|PubMed:9209038"
FT MUTAGEN 28
FT /note="D->N: Less than 10% activity."
FT /evidence="ECO:0000269|PubMed:9209038"
FT MUTAGEN 34
FT /note="R->A: Almost no effect."
FT /evidence="ECO:0000269|PubMed:9209038"
FT MUTAGEN 37
FT /note="W->F: 40% activity of wild-type."
FT /evidence="ECO:0000269|PubMed:9209038"
FT MUTAGEN 43
FT /note="R->A: Almost no effect."
FT /evidence="ECO:0000269|PubMed:9209038"
FT MUTAGEN 65
FT /note="T->A: Complete loss of activity."
FT /evidence="ECO:0000269|PubMed:9209038"
FT MUTAGEN 69
FT /note="E->D,N,Q: Complete loss of activity."
FT /evidence="ECO:0000269|PubMed:9209038"
FT MUTAGEN 73
FT /note="D->N: 50% activity of wild-type."
FT /evidence="ECO:0000269|PubMed:9209038"
FT MUTAGEN 76
FT /note="R->A: Almost no effect."
FT /evidence="ECO:0000269|PubMed:9209038"
FT MUTAGEN 102
FT /note="E->Q: 15% activity of wild-type."
FT /evidence="ECO:0000269|PubMed:9209038"
FT MUTAGEN 115
FT /note="Y->F: Almost no effect."
FT /evidence="ECO:0000269|PubMed:9209038"
FT MUTAGEN 117
FT /note="N->D: Less than 10% activity."
FT /evidence="ECO:0000269|PubMed:9209038"
FT MUTAGEN 119
FT /note="K->R: Almost no effect."
FT /evidence="ECO:0000269|PubMed:9209038"
FT MUTAGEN 120
FT /note="Y->F: Less than 10% activity."
FT /evidence="ECO:0000269|PubMed:9209038"
FT MUTAGEN 125
FT /note="S->A: 60% activity of wild-type."
FT /evidence="ECO:0000269|PubMed:9209038"
FT MUTAGEN 129
FT /note="E->Q: No effect."
FT /evidence="ECO:0000269|PubMed:9209038"
FT MUTAGEN 134
FT /note="R->A: 50% activity of wild-type."
FT /evidence="ECO:0000269|PubMed:9209038"
FT MUTAGEN 161
FT /note="E->Q: No effect."
FT /evidence="ECO:0000269|PubMed:9209038"
FT MUTAGEN 167
FT /note="D->N: No effect."
FT /evidence="ECO:0000269|PubMed:9209038"
FT MUTAGEN 193
FT /note="S->A: No effect."
FT /evidence="ECO:0000269|PubMed:9209038"
FT MUTAGEN 194
FT /note="D->A,E,G,N,S: Complete loss of activity."
FT /evidence="ECO:0000269|PubMed:9209038"
FT MUTAGEN 201
FT /note="W->F: 60% activity of wild-type."
FT /evidence="ECO:0000269|PubMed:9209038"
FT MUTAGEN 219
FT /note="T->A: Less than 10% activity."
FT /evidence="ECO:0000269|PubMed:9209038"
FT MUTAGEN 250
FT /note="D->N: Less than 10% activity."
FT /evidence="ECO:0000269|PubMed:9209038"
FT MUTAGEN 256
FT /note="T->A: Almost no effect."
FT /evidence="ECO:0000269|PubMed:9209038"
FT MUTAGEN 271
FT /note="N->D: Almost no effect."
FT /evidence="ECO:0000269|PubMed:9209038"
SQ SEQUENCE 307 AA; 34239 MW; 4CAD158995156ABD CRC64;
MSHRPILKNF PQVDHHQASG KLGDLYNDIH DTLRVPWVAF GIRVMSQFEH FVPAAWEALK
PQISTRYAEE GADKVREAAI IPGSAPANPT PALLANGWSE EEIAKLKATL DGLNYGNPKY
LILISAWNEA WHGRDAGGGA GKRLDSVQSE RLPYGLPQGV EKFHLIDPEA ADDQVQCLLR
DIRDAFLHHG PASDYRVLAA WPDYLEIAFR DTLKPVALTT EFELTTSRIR KIAREHVRGF
DGAGGVAWRD MADRMTPEEI AGLTGVLFMY NRFIADITVA IIRLKQAFGS AEDATENKFR
VWPTEKG
